immuno oncology frontiers world miami


Cade Hildreth

Cade Hildreth

BS, MS, President & CEO,
Cade Hildreth is the President and CEO of As the first and only market research firm to specialize in the stem cell industry, BioInformant has a robust 10-year database of historical information on which to base cord blood market predictions. Cade is also a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. Cade studied Biology and Chemistry at Dartmouth College, Biochemistry & Molecular Biology at Georgetown University, and Dental Medicine at the University of Pennsylvania. Outside the office, Cade is an elite rugby player, having represented the USA Women’s Rugby Team and the USA Touch Rugby Team.
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy